Page 2 - Jack Anders News Today

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript February 26, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]

Revolution Medicines (NASDAQ:RVMD – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.29), Briefing.com reports. Revolution Medicines had a negative net margin of 1,003.36% and a negative return on equity of 38.92%. The firm had revenue of $0.74 […]

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price […]

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) CFO Jack Anders sold 1,775 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $25.90, for a total value of $45,972.50. Following the sale, the chief financial officer now owns 76,416 shares in the company, […]

BVF Inc. IL increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 26.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,255,588 shares of the company’s stock after buying an additional 1,300,000 shares during the period. Revolution Medicines accounts for about […]

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $33.81 and last traded at $33.75, with a volume of 72758 shares changing hands. The stock had previously closed at $33.30. Analysts Set New Price Targets A number of research analysts […]

Revolution Medicines (NASDAQ:RVMD – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.10), Briefing.com reports. Revolution Medicines had a negative net margin of 744.36% and a negative return on equity of 36.79%. The business had […]

Victory Capital Management Inc. trimmed its position in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 5.9% in the 1st quarter, HoldingsChannel reports. The firm owned 45,410 shares of the company’s stock after selling 2,860 shares during the quarter. Victory Capital Management Inc.’s holdings in Revolution Medicines were worth $984,000 as of its most recent […]

HC Wainwright reissued their buy rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2023 earnings at ($0.81) EPS, Q3 2023 earnings at ($0.91) EPS, […]

Revolution Medicines (NASDAQ:RVMD – Free Report) had its price target increased by Needham & Company LLC from $31.00 to $35.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have a buy rating on the stock. A number of other research analysts have also recently commented on the company. JPMorgan Chase […]